Armed oncolytic viruses
US11298420B2 · kind B2 · utility
0Cited by
1References
43Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Dec 15, 2017 |
| Grant date | Apr 12, 2022 |
| Priority date | — |
| Expiry date | Dec 15, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are oncolytic viruses comprising chimeric human/mouse CD40 ligands. The chimeric human/mouse CD40 ligand may be MEM40. The oncolytic virus may be replication competent. The oncolytic virus may be an oncolytic herpes simplex virus. Also disclosed are methods comprising administering an oncolytic virus armed with at least one chimeric human/mouse CD40 ligand, for example MEM40, to a patient suffering from cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.